Teva has reached a settlement with Perrigo Pharmaceutical and Catalent Pharma Solutions with respect to four patents for Teva’s ProAir HFA (albuterol sulfate) Inhalation aerosol product.
An inhaler for patients with bronchospasm that includes a dose counter has become available from Teva Respiratory, the company said Thursday.
Perrigo is seeking regulatory approval for what it called the first generic version of a drug for treating bronchospasm.
The Food and Drug Administration has approved a version of a drug made by Teva that includes a dose counter, the drug maker said.
The Food and Drug Administration has approved a new product for chronic obstructive pulmonary disease made by Boehringer Ingelheim Pharmaceuticals, the drug maker said.